Emerging paradigms in GPCR allostery: Implications for drug discovery

Nature Reviews Drug Discovery

Volumn 12, Issue 8, 2013, Pages 630-644

  Wootten, Denise ^a   Christopoulos, Arthur ^a   Sexton, Patrick M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBACHOL; CARVEDILOL; CHEMOKINE RECEPTOR CCR5; CHLORPROPHAM; CINACALCET; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; IONOTROPIC RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCARINIC RECEPTOR; OXYNTOMODULIN; PILOCARPINE; PROTEINASE ACTIVATED RECEPTOR 1; RANTES; TETRAMETHYLAMMONIUM;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; CHOLINERGIC TRANSMISSION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; DISSOCIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; HEART FAILURE; HIGH THROUGHPUT SCREENING; HUMAN; INSULIN RELEASE; LIGAND BINDING; MOLECULAR PROBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; THERMODYNAMICS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 84881271660     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4052     Document Type: Review

References (120)

1. Jacoby, E., Bouhelal, R., Gerspacher, M. & Seuwen, K. The 7 TM G protein-coupled receptor target family. ChemMedChem 1, 761-782 (2006).
2. Melancon, B. J. et al. Allosteric modulation of seven transmembrane spanning receptors: Theory, practice, and opportunities for central nervous system drug discovery. J. Biol. Chem. 55, 1445-1464 (2012).
3. Kenakin, T. & Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304 (2010).
4. Valant, C., Lane, J. R., Sexon, P. M. & Christopoulos, A. The best of both worlds? Biotopic orthosteric/allosteric ligands of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52, 153-178 (2012).
5. Antony, J. et al. Dualsteric GPCR targeting: A novel route to binding and signaling pathway selectivity. FASEB J. 23, 442-450 (2009).
6. Steinfeld, T., Mammen, M., Smith, J. A., Wilson, R. D. & Jasper, J. R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol. Pharmacol. 72, 291-302 (2007).
7. Valant, C. et al. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283, 29312-29321 (2008).
8. Waelbroeck, M. Identification of drugs competing with d tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol. Pharmacol. 46, 685-692 (1994).
9. Christopoulos, A. & Mitchelson, F. Pharmacological analysis of the mode of interaction of McN A-343 at atrial muscarinic M2 receptors. Eur. J. Pharmacol. 339, 153-156 (1997).
10. Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M. & Christopoulos, A. Identification of orthosteric and allosteric site mutations in the M2 muscarinic acetylcholine receptors that contribute to ligand-selective signalling bias. J. Biol. Chem. 285, 7459-7474 (2010).
11. Langmead, C. J. et al. Probing the molecular mechanism of interaction between 4 n butyl 1-[4-(2 methylphenyl)-4 oxo 1 butyl]-piperidine (AC 42) and the muscarinic M1 receptor: Direct pharmacological evidence that AC 42 is an allosteric agonist. Mol. Pharmacol. 69, 236-246 (2006).
12. Avlani, V. A. et al. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol. Pharmacol. 78, 94-104 (2010).
13. Lebon, G., Langmead, C. J., Tehan, B. G. & Hulme, E. C. Mutageneic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 75, 331-341 (2009).
14. Chien, E. Y. et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095 (2010).
15. Disingrini, T. et al. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J. Med. Chem. 49, 366-372 (2006).
16. Narlawar, R. et al. Hybrid ortho/allosteric ligands for the adenosine A1 receptor. J. Med. Chem. 53, 3028-3037 (2010).
17. Kostenis, E. & Mohr, K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol. Sci. 17, 280-283 (1996).
18. May, L. T., Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51 (2007).
19. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187-194 (1988).
20. Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc. R. Soc. B Biol. Sci. 220, 141-162 (1983).
21. Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67, 1268-1282 (2005).
22. Krause, R. M. et al. Ivermectin: A positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53, 283-294 (1998).
23. Suratman, S. et al. Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br. J. Pharmacol. 162, 1659-1670 (2011).
24. Nawaratne, V., Leach, K., Felder, C. C., Sexton, P. M. & Christopoulos, A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: Identification of ligand-specific and global activation mechanisms. J. Biol. Chem. 285, 19012-19021 (2010).
25. Valant, C., Felder, C. C., Sexton, P. M. & Christopoulos, A. Probe dependence in the allosteric modulation of a G protein-coupled receptor: Implications for detection and validation of allosteric ligand effects. Mol. Pharmacol. 81, 41-52 (2012).
26. Chan, W. Y. et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl Acad. Sci. USA 105, 10978-10983 (2008).
27. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006).
28. Tao, Y. X. The melanocortin 4 receptor: Physiology, pharmacology, and pathophysiology. Endocr. Rev. 31, 506-543 (2010).
29. Gardella, T. J. & Juppner, H. Interaction of PTH and PTHrP with their receptors. Rev. Endocr. Metab. Disord. 1, 317-329 (2000).
30. Halls, M. L., van der Westhuizen, E. T., Bathgate, R. A. & Summers, R. J. Relaxin family peptide receptors - former orphans reunite with their parent ligands to activate multiple signalling pathways. Br. J. Pharmacol. 150, 677-691 (2007).
31. Conigrave, A. D., Quinn, S. J. & Brown, E. M. lamino acid sensing by the extracellular Ca2+-sensing receptor. Br. J. Pharmacol. 97, 4814-4819 (2000).
32. Poyner, D. R. et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 54, 233-246 (2002).
33. Estall, J. L. & Drucker, D. J. Glucagon and glucagon-like peptide receptors as drug targets. Curr. Pharm. Des. 12, 1731-1750 (2006).
34. Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends. Pharmacol. Sci. 28, 382-389 (2007).
35. Baker, J. G., Hall, I. P. & Hill, S. J. Agonist and inverse agonist actions of β-blockers at the human β2 adrenoceptor provide evidence for agonist-directed signaling. Mol. Pharmacol. 64, 1357-1369 (2003).
36. Wisler, J. W. et al. A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling. Proc. Natl Acad. Sci. USA 104, 16657-16662 (2007).
37. Goupil, E. et al. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2α mediated Rho/ROCK signaling pathway. J. Biol. Chem. 285, 25624-25636 (2010).
38. Makita, N. et al. An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca sensing receptor conformations. Proc. Natl Acad. Sci. USA 104, 5443-5448 (2007).
39. Canals, M., Sexton, P. M. & Christopoulos, A. Allostery in GPCRs: 'MWC' revisited. Trends. Biochem. Sci. 36, 663-672 (2011).
40. Leach, K. et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35, 855-869 (2010).
41. Koole, C. et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP 1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: Implications for drug screening. Mol. Pharmacol. 78, 456-465 (2010).
42. Wootten, D. et al. Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Mol. Pharmacol. 82, 281-290 (2012).
43. Willard, F. S. et al. Small molecule allosteric modulation of the glucagon-like peptide 1 receptor enhances the insulinotropic effect of oxyntomodulin. Mol. Pharmacol. 82, 1066-1073 (2012).
44. Stanley, S., Wynne, K. & Bloom, S. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G693-G697 (2004).
45. Sloop, K. W. et al. Novel small molecule glucagon-like peptide 1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59, 3099-3107 (2010).
46. Muniz-Medina, V. M. et al. The relative activity of "function sparing" HIV 1 entry inhibitors on viral entry and CCR5 internalization: Is allosteric functional selectivity a valuable therapeutic property? Mol. Pharmacol. 75, 490-501 (2009).
47. Gonzalez, E. et al. The influence of CCL3L1 gene-containing segmental duplications on HIV 1/AIDS susceptibility. Science 307, 1434-1440 (2005).
48. Willard, F. S. et al. Small molecule allosteric modulation of the glucagon-like peptide 1 receptor enhances the insulinotropic effect of oxyntomodulin. Mol. Pharmacol. 82, 1066-1073 (2012).
49. Gao, Z. G. et al. Functionally biased modulation of A3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem. Pharmacol. 82, 658-668 (2011).
50. Deacon, C. F., Johnsen, A. H. & Holst, J. J. Degradation of glucagon-like peptide 1 by human plasma in vitro yields an N terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952-957 (1995).
51. Birks, R. I. & Macintosh, F. C. Acetylcholine metabolism at nerve-endings. Br. Med. Bull. 13, 157-161 (1957).
52. Plagemann, P. G., Wohlhueter, R. M. & Kraupp, M. Adenosine uptake, transport, and metabolism in human erythrocytes. J. Cell. Physiol. 125, 330-336 (1985).
53. Tucek, S. et al. The concentration of choline and the activities of cholinesterases, creatine kinase and lactate dehydrogenase in the blood plasma of piglets with the syndrome of splayleg (congenital myofibrillar hypoplasia). Zentralbl. Veterinarmed. A 32, 1-10 (1985).
54. Backstrom, T., Goiny, M., Lockowandt, U., Liska, J. & Franco-Cereceda, A. Cardiac outflow of amino acids and purines during myocardial ischemia and reperfusion. J. Appl. Physiol. 94, 1122-1128 (2003).
55. Tomas, E., Stanojevic, V. & Habener, J. F. GLP 1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm. Metab. Res. 42, 657-662 (2010).
56. Canals, M. et al. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J. Biol. Chem. 287, 650-659 (2012).
57. Williams, R. et al. Re exploration of the PHCCC scaffold: Discovery of improved positive allosteric modulators of mGluR4. ACS Chem. Neurosci. 1, 411-419 (2010).
58. Schann, S. et al. Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators. J. Med. Chem. 53, 8775-8779 (2010).
59. Bridges, T. M. et al. Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. Bioorg. Med. Chem. Lett. 20, 558-562 (2010).
60. Bridges, T. M. et al. Discovery and development of a second highly selective M1 positive allosteric modulator (PAM). Probe Reports from the NIH Molecular Libraries Program [online], http://www.ncbi.nlm.nih.gov/books/ NBK50704/ (National Center for Biotechnology Information, 2010).
61. Borshell, N., Papp, T. & Congreve, M. Deal watch: Valuation benefits of structure-enabled drug discovery. Nature Rev. Drug Discov. 10, 166 (2011).
62. Lagerstrom, M. C. & Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Rev. Drug Discov. 7, 339-357 (2008).
63. Palczewski, K. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-745 (2000).
64. Rasmussen, S. G. et al. Crystal structure of the β2 adrenergic receptor Gs protein complex. Nature 477, 549-555 (2011).
65. Warne, T., Edwards, P. C., Leslie, A. G. & Tate, C. G. Crystal structures of a stabilized β1 adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20, 841-849 (2012).
66. Kruse, A. C. et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552-556 (2012).
67. Haga, K. et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551 (2012).
68. Granier, S. et al. Structure of the δ-opioid receptor bound to naltrindole. Nature 485, 400-404 (2012).
69. Wu, H. et al. Structure of the human κ-opioid receptor in complex with JDTic. Nature 485, 327-332 (2012).
70. Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322-327 (2011).
71. Lebon, G. et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474, 521-525 (2011).
72. Zhang, C. et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387-392 (2012).
73. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
74. Shimamura, T. et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 475, 65-70 (2011).
75. Runge, S., Thogersen, H., Madsen, K., Lau, J. & Rudolph, R. Crystal structure of the ligand-bound glucagon-like peptide 1 receptor extracellular domain. J. Biol. Chem. 283, 11340-11347 (2008).
76. Pioszak, A. A., Parker, N. R., Suino-Powell, K. & Xu, H. E. Molecular recognition of corticotropin-releasing factor by its G protein-coupled receptor CRFR1. J. Biol. Chem. 283, 32900-32912 (2008).
77. Tsuchiya, D., Kunishima, N., Kamiya, N., Jingami, H. & Morikawa, K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc. Natl Acad. Sci. USA 99, 2660-2665 (2002).
78. Muto, T., Tsuchiya, D., Morikawa, K. & Jingami, H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc. Natl Acad. Sci. USA 104, 3759-3764 (2007).
79. Matsui, H., Lazareno, S. & Birdsall, N. J. Probing of the location of the allosteric site on M1 muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 47, 88-98 (1995).
80. Trankle, C. et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl W84 at the common allosteric site of muscarinic M2 receptors. Mol. Pharmacol. 64, 180-190 (2003).
81. Prilla, S., Schrobang, J., Ellis, J., Holtje, H. D. & Mohr, K. Allosteric interactions with muscarinic acetylcholine receptors: Complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol. Pharmacol. 70, 181-193 (2006).
82. Avlani, V. A. et al. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J. Biol. Chem. 282, 25677-25686 (2007).
83. Dragic, T. et al. A binding pocket for a small molecule inhibitor of HIV 1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 97, 5639-5644 (2000).
84. Gerlach, L. O., Skerlj, R. T., Bridger, G. J. & Schwartz, T. W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 276, 14153-14160 (2001).
85. Maeda, K. et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281, 12688-12698 (2006).
86. Nicholls, D. J. et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol. Pharmacol. 74, 1193-1202 (2008).
87. Andrews, G., Jones, C. & Wreggett, K. A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol. Pharmacol. 73, 855-867 (2008).
88. Liaw, C. W., Grigoriadis, D. E., Lorang, M. T., De Souza, E. B. & Maki, R. A. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol. 11, 2048-2053 (1997).
89. Dupuis, D. S., Relkovic, D., Lhuillier, L., Mosbacher, J. & Kaupmann, K. Point mutations in the transmembrane region of GABAB2 facilitate activation by the positive modulator N,NŶ dicyclopentyl-2 methylsulfanyl-5 nitro-pyrimidine 4,6 diamine (GS39783) in the absence of the GABAB1 subunit. Mol. Pharmacol. 70, 2027-2036 (2006).
90. Pagano, A. et al. The non-competitive antagonists 2 methyl 6-(phenylethynyl)pyridine and 7 hydroxyiminocyclopropan[b]chromen-1a carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 275, 33750-33758 (2000).
91. Knoflach, F. et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site. Proc. Natl Acad. Sci. USA 98, 13402-13407 (2001).
92. Petrel, C. et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor. J. Biol. Chem. 278, 49487-49494 (2003).
93. Malherbe, P. et al. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 278, 8340-8347 (2003).
94. Miedlich, S. U., Gama, L., Seuwen, K., Wolf, R. M. & Breitwieser, G. E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279, 7254-7263 (2004).
95. Cisowski, J. et al. Targeting protease-activated receptor 1 with cell-penetrating pepducins in lung cancer. Am. J. Pathol. 179, 513-523 (2011).
96. Tressel, S. L. et al. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol. Biol. 683, 259-275 (2011).
97. Rosenbaum, D. M. et al. Structure and function of an irreversible agonist-β2 adrenoceptor complex. Nature 469, 236-240 (2011).
98. Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175-180 (2011).
99. Horstman, D. A. et al. An aspartate conserved among G protein receptors confers allosteric regulation of alpha 2 adrenergic receptors by sodium. J. Biol. Chem. 265, 21590-21595 (1990).
100. Costa, T., Lang, J., Gless, C. & Herz, A. Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: Specific regulation by antagonists and sodium ions. Mol. Pharmacol. 37, 383-394 (1990).
101. Gao, Z. G. & Ijzerman, A. P. Allosteric modulation of A2A adenosine receptors by amiloride analogues and sodium ions. Biochem. Pharmacol. 60, 669-676 (2000).
102. Selent, J., Sanz, F., Pastor, M. & De Fabritiis, G. Induced effects of sodium ions on dopaminergic G protein coupled receptors. PLoS Comput. Biol. 6, e1000884 (2010).
103. Neve, K. A. et al. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol. Pharmacol. 60, 373-381 (2001).
104. Parker, M. S., Wong, Y. Y. & Parker, S. L. An ion-responsive motif in the second transmembrane segment of rhodopsin-like receptors. Amino Acids 35, 1-15 (2008).
105. Vroling, B. et al. GPCRDB: Information system for G protein-coupled receptors. Nucleic Acids Res. 39, D309-D319 (2011).
106. Liu, W. et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337, 232-236 (2012).
107. Standfuss, J. et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471, 656-660 (2011).
108. Rocheville, M. et al. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157 (2000).
109. El Asmar, L. et al. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 67, 460-469 (2005).
110. Ellis, J., Pediani, J. D., Canals, M., Milasta, S. & Milligan, G. Orexin 1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J. Biol. Chem. 281, 38812-38824 (2006).
111. Harikumar, K. G. et al. Glucagon-like peptide 1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc. Natl Acad. Sci. USA 109, 18607-18612 (2012).
112. Harikumar, K. G., Ball, A. M., Sexton, P. M. & Miller, L. J. Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization. Regul. Pept. 164, 113-119 (2010).
113. Harikumar, K. G., Happs, R. M. & Miller, L. J. Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. Biochim. Biophys. Acta. 1778, 2555-2563 (2008).
114. Harikumar, K. G., Pinon, D. I. & Miller, L. J. Transmembrane segment IV contributes a functionally important interface for oligomerization of the class II G protein-coupled secretin receptor. J. Biol. Chem. 282, 30363-30372 (2007).
115. Gao, F. et al. Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol. Pharmacol. 76, 264-274 (2009).
116. El Moustaine, D. et al. Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G protein coupling. Proc. Natl Acad. Sci. USA 109, 16342-16347 (2012).
117. Block, G. et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350, 1516-1525 (2004).
118. Brown, E. M. Clinical lessons from the calcium sensing receptor. Nature Clin. Pract. Endocrinol. Metab. 3, 122-133 (2007).
119. Fatkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV 1. Nature Med. 11, 1170-1172 (2005).
120. Wood, A. & Armour, D. The discovery of the CCR5 receptor antagonist, UK 427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43, 239-271 (2005).